Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS • Currently down 0.40 (-1.90%) in today's trading session

1 member of Congress has disclosed 1 trade in Sarepta Therapeutics, Inc. (SRPT) via STOCK Act filings. The most recent disclosure was a purchase by Josh Gottheimer on 6 March 2023. Aggregate disclosed activity totals roughly $8K in purchases (midpoint estimates from bracketed disclosure amounts).

Sarepta Therapeutics, Inc. is currently trading at $20.67, positioned at 19% of its 52-week range ($10.42 – $64.80).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$20.67
24h Change
-0.40 (-1.90%)
52 Week Range
$10.42—$64.80
View on NASDAQ

Sarepta Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for SRPT

Select to highlight on chart
1 transactions
Compliance: 100%
Josh Gottheimer6 Mar 202320 Apr 2023PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.17B

Volume

1.45M

Beta

0.28

P/E Ratio

-2.90

Fundamentals

EPS

$-7.13

Div. Yield

—

Open

$20.89

Day Range

$20.30 — $20.89

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Douglas S. Ingram
IPO Date
1997-06-04
Website
www.sarepta.com

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EX...

Earnings

Next Report

Q1 2026

6 May

EPS Est.

$0.98

Rev. Est.

$474.2M

Days Until

6

Recent Quarters

Q4 202525 Feb
EPS$-3.58
Miss 247.6%
Q3 20253 Nov
EPS$-0.13
Miss 1400.0%
Q2 20256 Aug
EPS$2.02
Beat 82.0%
Q1 20256 May
EPS$-3.42
Miss 1077.1%
Q4 202426 Feb
EPS$1.50
Beat 8.7%
Q3 20246 Nov
EPS$0.62
Beat 1139.8%
Q2 20247 Aug
EPS$0.07
Beat 1201.1%
Q1 20241 May
EPS$0.73
Beat 625.6%
Q4 202328 Feb
EPS$0.47
Beat 3084.3%
Q3 20231 Nov
EPS$-0.46
Beat 72.3%
Q2 20232 Aug
EPS$-0.27
Beat 85.7%
Q1 20232 May
EPS$-0.97
Beat 33.6%
Q4 202228 Feb
EPS$-1.24
Beat 3.1%
Q3 20222 Nov
EPS$-2.94
Miss 143.0%
Q2 20222 Aug
EPS$-2.65
Miss 147.7%
Q1 20224 May
EPS$-1.20
Beat 11.1%
Q4 20211 Mar
EPS$-1.42
Beat 6.0%
Q3 20213 Nov
EPS$-0.60
Beat 67.7%
Q2 20214 Aug
EPS$-1.02
Beat 1.0%
Q1 20215 May
EPS$-2.10
Miss 4.5%
Q4 20201 Mar
EPS$-2.40
Miss 20.0%
Q3 20205 Nov
EPS$-2.50
Miss 32.3%
Q2 20205 Aug
EPS$-1.93
Miss 6.6%
Q1 20206 May
EPS$-0.23
Beat 90.0%
Q4 201926 Feb
EPS$-3.16
Miss 72.7%
Q3 20197 Nov
EPS$-1.70
Miss 26.9%
Q2 20197 Aug
EPS$-3.74
Miss 246.3%
Q1 20198 May
EPS$-1.07
Beat 47.8%
Q4 201827 Feb
EPS$-0.85
Miss 28.8%
Q3 201824 Oct
EPS$-0.56
Miss 64.7%
Q2 20188 Aug
EPS$-0.43
Beat 8.5%
Q1 20183 May
EPS$-0.28
Beat 12.5%
Q4 20171 Mar
EPS$-0.37
Miss 19.4%
Q3 201725 Oct
EPS$-0.78
Beat 9.3%
Q2 201719 Jul
EPS$-1.15
Miss 25.0%
Q1 201727 Apr
EPS$-0.73
Beat 14.1%
Q4 201628 Feb
EPS$-1.58
Miss 25.4%
Q3 201627 Oct
EPS$-1.18
Beat 12.6%
Q2 201619 Jul
EPS$-1.35
Miss 13.4%
Q1 20165 May
EPS$-1.31
Miss 0.8%
Q4 201525 Feb
EPS$-1.44
Miss 20.0%
Q3 20155 Nov
EPS$-1.25
Miss 5.0%
Q2 20156 Aug
EPS$-1.01
Beat 16.5%
Q1 20157 May
EPS$-1.49
Miss 49.0%
Q4 201426 Feb
EPS$-0.94
Miss 13.3%
Q3 20146 Nov
EPS$-0.71
Beat 25.3%
Q2 20147 Aug
EPS$-0.61
Beat 21.8%
Q1 20148 May
EPS$-0.75
Beat 6.3%
Q4 201327 Feb
EPS$-0.23
Beat 67.1%
Q3 201312 Nov
EPS$-0.63
Beat 4.5%
Q2 20138 Aug
EPS$-0.60
Beat 16.7%
Q1 20139 May
EPS$-0.41
Beat 25.4%
Q4 20127 Mar
EPS$-0.39
Miss 2.6%
Q3 20127 Nov
EPS$-0.30
Miss 3.5%
Q2 20127 Aug
EPS$0.35
Beat 266.7%
Q1 201210 May
EPS$-0.78
Miss 77.3%
Q4 20111 Mar
EPS$-0.06
Beat 81.8%
Q3 20113 Nov
EPS$-0.18
Beat 48.6%
Q2 20114 Aug
EPS$0.06
Beat 115.0%
Q1 20115 May
EPS$0.12
Beat 163.2%
Q4 201010 Mar
EPS$-0.42
Beat 0.0%
Q3 20109 Nov
EPS$-0.42
Miss 16.7%
Q2 20109 Aug
EPS$-0.90
Miss 200.0%
Q1 201010 May
EPS$-0.06
Beat 77.8%
Q4 200916 Mar
EPS$0.18
Beat 166.7%
Q3 20099 Nov
EPS$-0.48
Miss 23.1%
Q2 200910 Aug
EPS$-1.38
Miss 1050.0%
Q1 200911 May
EPS$-0.06
Beat 77.8%
Q4 200810 Mar
EPS$-0.06
Beat 83.3%
Q3 200810 Nov
EPS$-0.48
Miss 23.1%
Q2 200811 Aug
EPS$-0.12
Beat 73.3%
Q1 200812 May
EPS$-1.38
Miss 206.7%
Q4 200712 Mar
EPS$-0.42
Beat 12.5%
Q3 20076 Nov
EPS$-0.78
Miss 8.3%
Q2 20078 Aug
EPS$-0.96
Miss 28.0%
Q1 20079 May
EPS$-1.08
Miss 38.5%
Q4 200615 Mar
EPS$-0.96
Miss 14.3%
Q3 20068 Nov
EPS$-0.78
Beat 7.1%
Q2 20068 Aug
EPS$-0.78
Miss 18.2%
Q1 20065 May
EPS$-1.08
Miss 200.0%
Q4 20058 Mar
EPS$-0.60
Beat 4.8%
Q3 20054 Nov
EPS$-0.24
Beat 68.4%
Q2 20058 Aug
EPS$-0.66
Beat 5.7%
Q1 20059 May
EPS$-0.78
Miss 8.3%
Q4 20048 Mar
EPS$-0.84
Beat 3.5%
Q3 20044 Nov
EPS$-0.84
Beat 0.0%
Q2 20045 Aug
EPS$-1.20
Beat 2.4%
Q1 20045 May
EPS$-1.26
Miss 50.0%
Q4 20039 Mar
EPS$-1.26
Miss 43.2%
Q3 20034 Nov
EPS$-0.90
Miss 12.5%
Q2 20035 Aug
EPS$-0.72
Beat 0.0%
Q1 20036 May
EPS$-0.78
Beat 21.2%
Q4 200231 Mar
EPS$-0.90
Q4 200211 Mar
EPS$-0.90
Beat 30.2%
Q2 20026 Aug
EPS$-1.80
Miss 66.7%
Q1 20027 May
EPS$-1.98
Miss 94.1%
Q1 20021 Apr
EPS$-1.18
Q4 200112 Mar
EPS$-1.20
Miss 5.3%
Q2 200114 Aug
EPS$-0.98
Q1 200110 May
EPS$-0.89
Q4 200027 Mar
EPS$-0.84
Q3 20009 Nov
EPS$-0.67
Q2 20009 Aug
EPS$-1.02
Q1 200010 May
EPS$-0.42
Q4 199929 Feb
EPS$-0.88
Q3 199912 Nov
EPS$-0.99
Q2 199912 Aug
EPS$-0.90
Q1 199913 May
EPS$-0.78
Q4 199830 Mar
EPS$-1.10
Q3 199813 Nov
EPS$-11.04
Q2 199811 Aug
EPS$-0.90
Q1 199812 May
EPS$-0.78
Q4 199730 Mar
EPS$-0.45
Q3 199712 Nov
EPS$-0.54
Q2 19978 Aug
EPS$-0.78
Q4 199631 Mar
EPS$-0.19
Q3 199631 Dec
EPS$-0.47
Q2 199630 Sept
EPS$-0.39
Q1 199630 Jun
EPS$-0.43
Q4 199531 Mar
EPS$-0.21

No dividend data available for this stock.

Stock Splits

Split History

12 Jul 2012Reverse Split
Ratio1:6

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

NVDA

NVIDIA Corporation

20
$209.25-3.82 (-1.79%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

PTSNX

PIMCO Short Term I-3

17
$9.680.00 (0.00%)
Held by same politician
1 politician
View Stock

GOOG

Alphabet Inc.

17
$347.31-0.19 (-0.05%)
Communication Services
Held by same politician
1 politician
View Stock

Frequently Asked Questions about SRPT

Which members of Congress have traded SRPT?
1 member of Congress has disclosed 1 trade in Sarepta Therapeutics, Inc. (SRPT) under the STOCK Act: Josh Gottheimer.
When was SRPT most recently disclosed by Congress?
The most recent SRPT disclosure was a purchase by Josh Gottheimer on 6 March 2023.
What is the total disclosed congressional trading volume for SRPT?
Members of Congress have disclosed approximately $8K in SRPT purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in SRPT?
This SRPT page updates as soon as new STOCK Act disclosures are filed for Sarepta Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.